Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).

Authors

null

Ansh Kapil

AstraZeneca Computational Pathology GmbH, Early Oncology Translational Medicine, Munich, Germany;

Ansh Kapil , Henrik Failmezger , Andreas Spitzmüller , Jessica Chan , Susanne Haneder , Anatoliy Shumilov , Alice Barkell , Toshihiro Oguma , Koichiro Inaki , Fumitaka Suto , John Allard , Jeeyun Lee , J Carl Barrett , Günter Schmidt , Hadassah Sade , Danielle Carroll , Fabiola Cecchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT03329690, NCT04014075

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 449)

DOI

10.1200/JCO.2023.41.4_suppl.449

Abstract #

449

Poster Bd #

K15

Abstract Disclosures

Similar Posters

Poster

2013 Gastrointestinal Cancers Symposium

Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.

Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.

First Author: Tetsuya Kusumoto

First Author: Seyoung Seo

Poster

2015 Gastrointestinal Cancers Symposium

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

First Author: Ozge Gumusay